|Mr. Justin D. Gover||CEO & Exec. Director||1.19M||4.11M||1971|
|Mr. Scott M. Giacobello||Chief Financial Officer||743.33k||253.81k||1970|
|Mr. Douglas B. Snyder||Chief Legal Officer||787.02k||244.37k||1964|
|Dr. Volker Knappertz M.D., D.Sc.||Chief Medical Officer||830.47k||288.48k||1965|
|Mr. Christopher John Tovey||Chief Operating Officer||N/A||N/A||1965|
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
GW Pharmaceuticals plc’s ISS Governance QualityScore as of December 7, 2019 is 4. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 5.